



HAL
open science

A noncanonical- GPRC5A signaling regulates keratinocyte adhesion and migration by nuclear translocation

Sarah Chanteloube, Choua Ya, Gabrielle Le Provost, Aurore Berthier, Cindy Dieryckx, Sandrine Vadon-Le Goff, Florence Nadal, Bérengère Fromy, Romain Debret

► **To cite this version:**

Sarah Chanteloube, Choua Ya, Gabrielle Le Provost, Aurore Berthier, Cindy Dieryckx, et al.. A noncanonical-GPRC5A signaling regulates keratinocyte adhesion and migration by nuclear translocation. *FASEB Journal*, 2025, 39 (2), pp.e70323. <10.1096/fj.202400122R>. <hal-04933989>

HAL Id: hal-04933989

<https://hal.science/hal-04933989v1>

Submitted on 7 Feb 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

A noncanonical-GPRC5A signaling regulates keratinocyte adhesion and migration by nuclear translocation

Sarah Chanteloube¹, Choua Ya^{1,2}, Gabrielle Le Provost¹, Aurore Berthier¹, Cindy Dieryckx¹, Sandrine Vadon-Le Goff¹, Florence Nadal², Bérengère Fromy¹, Romain Debret^{1*}

¹ Laboratory of Tissue Biology and Therapeutic Engineering, UMR5305 CNRS, University Lyon 1, 7 Passage du Vercors, 69367 Lyon Cedex 07, France.

² Isispharma Dermatologie, Immeuble Le Dauphiné Part-Dieu, 78 rue de la Villette, 69003 Lyon, France.

* Corresponding author:

Romain DEBRET

LBTI, UMR 5305 CNRS/UCBL

7 Passage du Vercors

69367 Lyon Cedex 07, France

Tel : +334 72 72 26 40

E-mail : romain.debret@ibcp.fr

Abbreviations:

GPRC5A	G-Protein Coupled Receptor, Class C, Group 5, Member A
N-TAILS	N-terminal amine isotopic labeling
ECM	Extracellular matrix
AFM	Atomic force microscopy
GPCRs	G protein-coupled receptors
RAI3	Retinoic acid-induced protein 3
MS	Mass spectrometry
LC	Liquid phase
KD	Knock-down
RHE	Reconstructed human epidermis
TEWL	Transepidermal water loss

ABSTRACT

G-Protein Coupled Receptor, Class C, Group 5, Member A (GPC5A) has been extensively studied in lung and various epithelial cancers. Nevertheless, its role in the skin remains to be elucidated. In this study, we sought to investigate the function of this receptor in skin biology. Our research demonstrated that its expression responds to mechanical substrate changes in human primary keratinocytes. Furthermore, we observed the reinduction of GPC5A during wound healing at the leading edges in an *ex vivo* burn model, coinciding with the translocation of its C-terminal region into the nucleus. We identified the cleavage site of GPC5A by N-TAILS analysis, and cathepsin G was characterized as the protease responsible for proteolysis in cultured cells.

In order to gain a deeper understanding of the role of GPC5A in keratinocytes, we performed a GPC5A knockdown in N/TERT-1 cells using short-hairpin RNA. Our findings indicate a strong association between GPC5A and adhesion regulation pathways. Additionally, our results demonstrate that GPC5A^{KD} enhances cell adhesion while reducing cell migration and differentiation. It is noteworthy that these effects were reversed by the addition of a recombinant polypeptide that mimics the C-terminal region of GPC5A.

In conclusion, our study reveals that GPC5A plays an unexpected role in regulating keratinocyte behavior, with implications for its C-terminal region translocation into the nucleus. These results offer promising avenues for future research in the field of wound healing.

KEYWORDS

Receptors, G-Protein-Coupled ; keratinocytes ; wound healing ; skin ; mechanotransduction, cellular ; signal transduction ; cell nucleus

INTRODUCTION

In addition to the biomechanical properties of the extracellular matrix (ECM), mechanical cues influence cell behavior. Mechanotransduction refers to the conversion of mechanical information to biochemical cascades and has been involved in regulating keratinocyte functions to maintain epidermal homeostasis as it can regulate their proliferation, differentiation, morphology, and migration (1-3). *In vitro* studies have demonstrated that keratinocytes respond to mechanical signals and may dictate how skin and cutaneous wounds interact with the environment (4) (5). It has been established that substrate stiffness can promote keratinocyte proliferation and migration, while inhibiting the differentiation process (6). Furthermore, the substrate stiffness regulates the epidermal barrier through Jun kinase pathway phosphorylation which contributes to adherent junction formation (7). According to these observations, keratinocyte mechanotransduction is a crucial process in epidermal homeostasis and an improper process can cause many pathological changes, including impaired wound healing (1). Chen et al. reported a correlation between stiffness and skin wound healing, indicating that optimal stiffness is essential for enhanced wound healing (8). The ECM stiffness provides favorable conditions and support for the initiation of keratinocyte migration, whereas abnormal ECM mechanical properties result in defects in skin repair (9). Immediately after the injury, the basement membrane disappears, and the keratinocytes start to migrate on the underlying dermis ECM mostly composed of blood platelets and fibrin. This clot will be rapidly replaced by the fibroblasts in an ECM rich in fibronectin, tenascin C and type III collagen to form the granulation tissue (10). Hinz et al. demonstrated that the provisional matrix from rat wounded skin exhibited an increase in stiffness from 10kPa in the healthy dermis to 18 kPa at 7 days post-wounding and 50 kPa at 12 days, as measured by atomic force microscopy (AFM) (11).

In particular, the mechanotransduction system in the epidermis involves the participation of several protein complexes, including the cytoskeletal elements (e.g. F-actin, intermediate filament, and microtubules), mechanically activated ion channels (e.g. Connexin, Piezo, calcium sensing receptors, transient receptor potential), focal adhesions, integrins, adhesion receptors, and G protein-coupled receptors (GPCRs) (3). Several studies have indicated that certain GPCRs can be activated by mechanical forces, such as cellular stretching or compression in endothelial cells and cardiac tissue (7, 12-14). Investigations conducted on keratinocytes have provided evidence that GPCRs regulate cell proliferation, differentiation, and migration (15-17). However, it is noteworthy that, despite the apparent role of GPCRs in epidermal homeostasis, no current study has conclusively demonstrated that mechanical properties of the keratinocytes' microenvironment could modulate their expression or activity independently of their ligand redistribution.

The present study provides evidence that a specific orphan GPCR, G-Protein Coupled Receptor, Class C, Group 5, Member A (GPRC5A), plays a pivotal role in governing human keratinocyte behavior by modulating both the adhesion and migration processes. Furthermore, GPRC5A seems intricately involved in epidermal differentiation, as its deficiency disrupts proper stratification. Our working hypothesis posits that keratinocytes exhibit responsiveness to alterations in tissue stiffness during wound healing, thereby triggering the initiation of the reepithelization phase. Consequently, the present study employs *in vitro* and *ex vivo* human models to investigate the role of GPRC5A in the early stages of wound healing with the objective of enhancing the wound re-epithelialization process.

MATERIALS AND METHODS

Ethical considerations

Infant foreskins were collected according to the Declaration of Helsinki Principles. A written informed consent was obtained from infants' parents according to the French bioethical law of 2004. Abdominal adult skin explants were collected from the Biological Resource Center GCS/CTC (AC-2019-3476, 2nd July 2020) hosted by Hospices Civils de Lyon, in France.

Cell culture

The human primary epidermal keratinocyte cultures were obtained from child foreskin biopsies or women abdominoplasty after enzymatic treatment as described in (18). N/TERT-1 cell line was obtained from Rheinwald's lab (19). Keratinocytes were cultivated at 37°C in a 5% CO₂ atmosphere in a « keratinocyte serum-free medium (Ker-SFM, GIBCO) » completed with 25 µg/ml bovine pituitary extract, penicillin/streptomycin (100X), 0.2 ng/ml Epidermal Growth Factor and 0.3 mM CaCl₂. Presence of mycoplasma in cell cultures was detected regularly using MycoAlert assay (Lonza).

RNA interference

siRNA targeting human GPRC5A (siGPRC5A_4 against target sequence 5'-CTGGGTGTGTTGGGCATCTTT-3', cat# SI04438021) and non-targeting control siRNA (cat# Ctrl_AllStars_1, target sequence not disclosed) were purchased from Qiagen. Human primary keratinocytes were transfected at 20 nM final siRNA concentration using Lipofectamin 2000 reagent (Life Technologies) according to the manufacturer's instructions.

Generation of polyacrylamide hydrogels

The hydrogels were synthesized according to the principle described previously by (20). Briefly, 18 mm diameter coverslips were activated with 70 mM NaOH solution and heated at

80°C. This step was repeated with milliQ water until NaOH forms a thin semi-transparent film. The coverslips were treated for 5 min with APES (3-Aminopropyltriethoxysilane, Sigma) and thoroughly rinsed. Then, 0.5% glutaraldehyde (Sigma) was added onto the coverslips for 30 min and dried few minutes at room temperature. In parallel, 24x60 mm glass slides were chlorosilanated with DCDMS (dichlorodimethylsilane, Sigma) for 5 min, gently rinsed, and dried for 30 min at room temperature.

Polyacrylamide gels with different modulus of elasticity values were produced by mixing acrylamide/bis-acrylamide solutions at final percentages (p/v) of 3/0.1, 4/0.225 and 10/0.225 for Soft, Medium and Rigid hydrogels respectively. The polymerization is initiated with APS (ammonium persulfate, Sigma) and TEMED (N,N,N',N'-tetramethylethane-1,2-diamine, Sigma). The polyacrylamide solution is immediately pipetted onto the chlorosilanated slide and covered by the functionalized coverslip. After the completed polymerization, the top coverslip with the attached polyacrylamide gel is slowly peeled off and rinsed to take out DCDMS on the gel surface.

To facilitate keratinocyte attachment, a heterobifunctional crosslinker, sulfo-SANPAH (sulfosuccinimidyl6(4-azido-2-nitrophenyl-amino)hexanoate, ThermoFisher Scientific), is used to crosslink extracellular matrix molecules onto the surface of the gel. 0.2 mg/mL sulfo-SANPAH solution is added to gel surface, placed 3 inches under an ultraviolet lamp, irradiated for 10 min and rinsed with water. Then, 100 µg/mL of rat tail collagen I solution (ThermoFisher Scientific) is added on the gel and incubated for 2 h at room temperature under a 50 rpm agitation. Hydrogels were rinsed in PBS (phosphate buffered saline), placed in 12-well plates, and immersed in culture media at 37°C one night prior to cell seeding.

mRNA extraction and qRT-PCR

Total RNA was extracted using RNeasy mini kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Reverse transcription was performed using PrimeScript™ RT Reagent Kit (Takara, Tokyo, Japan). qRT-PCR was performed on a Mx3000P real-time PCR system (Stratagene, San Diego, CA, USA) using SYBR® Premix Ex Taq™ II (TaKaRa). Specific primers for RPL13, RPLP0 (ribosomal housekeeping gene) and GPRC5A were used (**Table S1**). The delta delta Ct method was used to calculate the relative fold change.

RNA sequencing

Samples processing

Cells were cultured on a glass substrate and soft hydrogel for 3 days and total RNA was extracted using RNeasy mini kit (Qiagen). RNA quantity and purity were verified using 2200 TapeStation system (Agilent Technologies). Library preparation was performed using mRNA-Seq Library Prep Kit Lexogen following the manufacturer's instructions. Libraries were validated on TapeStation – HSD1000 ScreenTape® Dosage. Barecoded libraries were pooled together (three per run) on an equimolar basis and run using PI chips on an Ion Torrent™ PGM sequencer using HiQ chemistry. Library preparation and sequencing were achieved by the IGFL sequencing platform (Lyon, France).

Bioinformatic analysis

Reads were aligned to the human reference genome hg19 using the Ion Torrent RNASeqAnalysis plugin. Two consecutive alignments were achieved through the STAR and Bowtie2 programs to generate the BAM files. Reads over genes were determined using the R/Bioconductor “Rsubread” software package to create a counts matrix (21). Differential gene expression analysis was performed using R/Bioconductor “limma” and “edgeR” software packages (22-24). Heat map were generated from limma-voom normalized values in R (25). Genes with a differential expression $FDR \leq 0.05$ were considered significant (**Table S2**).

Infection with lentiviral particles

Mission™ lentiviral transduction particles were purchased from Sigma. The pLKO puro lentiviral vector expressed a short hairpin RNA (shRNA) sequence targeting GPRC5A mRNA (shGPRC5A TRCN0000005628) or a control sRNA (shCTR SHC002V). Infection was performed on subconfluent N/TERT-1 cells at a multiplicity of infection of 1, in KGM2 medium supplemented with 1 µg/ml Polybrene (Sigma). Cells that integrated the lentiviral vectors were selected with 1µg/ml Puromycin (Sigma).

Analysis of kinase's phosphorylation rate

N/TERT-1 sh-CTRL and sh-GRPC5A cells were plated in 20mm² culture dishes in a complete Ker-SFM medium. After 2 and 24 hours of culture at 37°C, cells were washed with PBS and frozen at -80°C overnight. Levels of protein phosphorylation were then detected using the Human phospho-kinase Array Kit (ARY003B, R&D Systems) according to the manufacturer's instructions (**Table S3**). Optical density was analysed using ImageJ software for each spot of the array.

Cell proliferation assays

The cell proliferation rate of transfected keratinocytes with shRNA control or shRNA GPRC5A was measured after 1 to 3 days, using the alamarBlue™ cell viability reagent (Life Technologies). Cells were seeded and the proliferation rate was analyzed by adding 10% of alamarBlue reagent in fresh culture medium and incubated for 4 hours. The fluorescence intensity (excitation 570nm/emission 585nm) was measured using Tecan Infinite M1000 (Life Technologies).

For DNA quantification (Quant-iT™ PicoGreen™ dsDNA Assay Kit), cells were seeded in 96-well plates and DNA concentration was assessed according to the manufacturer's instructions.

Cell adhesion assays

Percoll assay

Adhesion assay was performed as described in (26). 96-well plates were coated either with 100 µg/ml of collagen type I (Life Technologies) or 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS) (negative control). Cells were trypsinized with 10 mM EDTA for 10 min at 37°C and washed twice with serum-free medium. Then 2.5×10^4 cells/well were re-suspended in a serum-free medium and plated in 5 replicas for each condition. Cells were allowed to attach for 5, 10, 30, 60, 120 and 240 min at 37°C, then unattached cells were removed with Percoll solution containing 0.57 mM NaCl. The remaining cells were fixed with Percoll solution containing 5% of glutaraldehyde for 15 min at room temperature. The cells were stained with 0.1% Crystal Violet for 30 min at room temperature, and then the plates were washed with water tap. Plates were air dried, and the crystal violet was then extracted using 2% SDS in distilled water for 30 min on a shaker. Absorbance at 570 nm was measured on Tecan Infinite M1000 (Life Technologies). Background absorbance (from blank wells) was subtracted from all test wells. The assay was always performed in 5 technical and 3 biological replicas.

Impedance measurement

Impedance of cells was measured using the xCELLigence system (Agilent Technologies, Les Ulis, France) Briefly, E-plates were coated with 100 µg/ml of type I Collagen and then saturated with 0,1% BSA (w/v). Cells were pre-treated or not with 10 µg/ml of mimetic peptide, during 24 hours before being harvested and replated in the E-plate (20 000 cells/well in 100 µl) in 4 technical replicates. Impedance is then measured for at least 5 hours after plugging the E-plate in the xCELLigence system placed inside the incubator at 37°C.

Cell migration assays

Ibidi insert

In 6-well plate, cells (2×10^4 cells/well) were seeded in 2-well silicone insert (Ibidi) for 30 hours. After confluence, the culture insert was slowly removed. After washing with PBS, the cells were supplied with a 2 ml culture medium. The cells were then allowed to migrate into the gap (500 μm) after 12, 14, 16, 18, 20, 22 and 24 hours. Quantification of cell migration was performed by measuring uncovered areas using Image J software. Each experiment was repeated in 3 technical and 3 biological replicates.

Scratch assay

Cells were seeded in 24-well plate ($2,5 \times 10^5$ cells/well), beforehand coated with 100 $\mu\text{g/ml}$ of Collagen type I. After 24 hours of adhesion, cells were then either treated or not with 10 $\mu\text{g/ml}$ of mimetic peptide for another 24 hours. Then a scratch is performed using some 20 μl tip, the cells are rinsed with PBS, fresh medium is added, and the closure of the wound is recorded using video microscopy (Zeiss Axio Observer 7) for 15 hours.

Western blot

Proteins were extracted in RIPA buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium deoxycholate, 0.1% SDS, 1 mM orthovanadate) and protease inhibitor cocktail (Thermo Fischer scientific). Lysates were centrifuged for 10 min at 14000 g at 4°C to eliminate cell debris. Protein concentration was finally measured using BCA assay (ThermoFischer). They were separated by SDS-PAGE followed by transfer to polyvinylidene fluoride membrane (EMD-Millipore, Billerica, MA). The membrane was blocked with 5 % non-fat milk in Tris buffered saline (TBS) buffer containing 0.1% Tween-20, and incubated with rabbit anti-GPRC5A antibody (HPA007928, Sigma, 1:250), mouse anti-actin (C4, MAB1501, Sigma-Aldrich, 1:5000), rabbit anti-Akt (9272, CellSignaling, 1:1000), rabbit anti-phospho-Akt (SER473) (9277S, CellSignaling, 1:1000) and rabbit anti-cathepsin G (703590, Invitrogen, 1:1000), overnight at 4°C. The membrane was incubated with secondary antibodies

for 1 h at room temperature: goat anti-rabbit IgG (H+L)-HRP conjugate (170-6510, Biorad, 1:10000) and goat anti-mouse IgG (H+L)-HRP conjugate (170-6516, Biorad, 1:10000). Antibody binding was detected by the enhanced chemiluminescence system (Thermo Fischer Scientific), using a Fusion Fx system (Vilber Lourmat) or iBright system (Invitrogen, Thermo Fischer Scientific).

Preparation of reconstructed epidermis

The reconstructed epiderma were produced according to the principle described previously by (27). Briefly, fibroblasts (2.5×10^4) were seeded underneath the polycarbonate membrane of the cell culture insert (Nunc, ThermoFischer Scientific). After 4 hours, the inserts were placed in 24-well plates, and fibroblasts were cultured for 2 days in DMEM/F12 (1/1) supplemented with 10 % fetal bovine serum (Fetal Clone II; Hyclone, Thermo Scientific, France) and 1% Penicillin/Streptomycin (Sigma). Then, N/TERT-1 infected by pLKO shRNA control or pLKO shRNA GPRC5A (2.5×10^5) were seeded on the top of the membrane and cultured for 3 days in DMEM/F12 (1/1) supplemented with 5 % fetal bovine serum (Fetal Clone II; Hyclone, Thermo Scientific, France), 0.2 ng/ml EGF (Gibco), 0.4 $\mu\text{g/ml}$ Hydrocortisone (Sigma), 5 $\mu\text{g/ml}$ Insulin (Sigma), 8 ng/ ml Cholera Toxin (Sigma), 2×10^{-11} M Tri-iodothyronine (Sigma), 24 $\mu\text{g/ml}$ Adenine (Sigma) and 1% Penicillin/Streptomycin. 24 hours the air/liquid interface, knock-down keratinocytes were treated or not with 10 $\mu\text{g/ml}$ of mimetic peptide. To induce stratification and differentiation, keratinocytes were then placed at the air/liquid interface and cultured for 2 days with the same medium, except that EGF and adenine were omitted, and the final concentration of calcium chloride (Sigma) was adjusted to 2 mM and 50 $\mu\text{g/ml}$ vitamin C. Cells were then cultured for another 14 days in the same medium, except that the foetal bovine serum was reduced to 1%. During the emersion phase, the culture medium was changed every day.

Functional evaluation of barrier function

Trans-epidermal water loss (TEWL) was measured using a Tewameter (TM 300) on 16 days RHE. The probe measures the density gradient of the water evaporation from the skin (in g/h/m²) indirectly by the two pairs of sensors (temperature and relative humidity) inside the hollow cylinder.

Human skin ex vivo injury model

A heated metal piece (2mm width, 150°C) was applied at the center of the skin sample for 3 seconds. Burned skins were then cultivated for 12 days on culture inserts to maintain the epidermis at the air/liquid interface. Skins were cultured in DMEM/F12 medium (Gibco) supplemented with Zellshield antibiotic (13-0150, Clinisciences).

Histology and immunofluorescence microscopy

RHE, human skin and cells on coverslip were fixed in 4% paraformaldehyde (PFA) solution, for 24 hours at 4°C. Samples were then embedded in paraffin and cut into 5 µm sections. After dewaxing and rehydration, tissue sections were stained with hematoxylin and eosin solutions for routine histology or permeabilized by 0.1% triton X100 for 10 min and then boiled in 10 nM citrate buffer pH6 for antigen retrieval. For immunocytofluorescent labelling, cells on coverslip were fixed for 10 minutes in 4% PFA solution. Then cells were permeabilized by 0.1% triton X100 for 10 minutes. Both skin sections and cells were then blocked by 5% of bovine albumin serum and incubated with the following primary antibodies overnight at 4°C. Cells were finally incubated with primary antibodies overnight: rabbit anti-GPRC5A (HPA007928, Sigma Aldrich, 1:250); rabbit anti-cytokeratin 10 [EP1607IHCY] (ab76318, Abcam, 1:500); mouse anti-cytokeratin 14 (MA5-11599, Invitrogen, 1:500), rabbit anti-involucrin (ab53112, Abcam, 1:500) and rabbit anti-cathepsin G (703590, Invitrogen, 1/100). Secondary antibodies were: alexa-488 and alexa-546 -conjugated goat anti-mouse IgG or anti-rabbit IgG (Molecular Probes, Life Technologies). Nuclear counterstaining using DAPI (4',6-

diamino-2-phenylindole) (Sigma) was carried out. Sections and coverslip were then mounted in ProLong™ Gold Antifade Mountant (Invitrogen). Image acquisition was performed using a fluorescent TiE Nikon microscope (Primatiss platform at LBTI), or a Leica SP5X confocal microscope (CIQLE platform “Centre d’imagerie Quantitative Lyon-Est de l’Université Lyon I”).

GPRC5A translocation kinetic

Primary keratinocytes were cultivated on soft polyacrylamide hydrogels (4kPa) for 3 days, then cells were transferred on stiff support (glass slide). During the transfer, keratinocytes were either treated or not with a Cathepsin G inhibitor (219372 – Sigma) at a concentration of 10 μ M for 30 minutes. Depending on the experiment, GPRC5A location was observed after 30 minutes, 1, 4 and 24 hours, but also after cells were confluent and 5 days post-confluency. Two different antibodies were used to label GPRC5A: rabbit anti-GPRC5A C-terminus (HPA007928, Sigma Aldrich, 1:250) targeting the C-terminal region of the receptor, and mouse anti-GPRC3A N-terminus (PA5-28738, Invitrogen, 1:250) targeting its N-terminal region. Intracellular compartment labelling was also performed using mouse anti-nucleolin (Ab154028, Abcam, 1/1000), concanavalin (C11252, Invitrogen, 1:100) and mouse anti-Golgi 58k (MA1-22144, Invitrogen, 1/250).

Mimetic C-ter peptide production and purification

GPRC5A C-terminal domain sequence was amplified from cultured keratinocytes and cloned into pET30a plasmid digested by EcoRV. Then a poly(R/K) tag was added by amplifying the C-ter sequence with some primer containing the tag, and the TEV-6His sequence was extracted from a pT7 plasmid to form a final plasmid pET30a_GPRC5A-C-terminal_poly(R/K)_TEV-cleavage-site_2x-6Histidines (**Table S4**).

BL21 bacteria were transformed with an overexpressing recombinant plasmid containing the C-terminal region of GPRC5A. The polypeptide was produced by adding 1 mM of IPTG in HYPER BROTH (AthenaES AE-0107) after bacteria arrived in the exponential growth phase. After 6 hours of culture, bacteria were centrifugated and protein were extracted: the soluble proteins with 500 mM NaCl, 10 mM MgCl₂ and 0.5% Triton X-100 solution, and then the insoluble part with 500 mM NaCl and 8 M urea solution.

Bacteria BL21 (Life Tech 44-048) were transformed with the plasmid pET30a_GPRC5A-C-terminal_poly(R/K)_TEV-cleavage-site_2x-6Histidines and subsequently cultured on LB-agar plates supplemented with kanamycin. A preculture was then initiated, where a single bacterial colony was inoculated into 100 mL of LB BROTH LENNOX medium (Formedium LBX0102) and incubated overnight at 37°C with agitation at 150 rpm. From this preculture, bacteria were inoculated to an optical density (D.O) of 0.15 in HYPER BROTH medium (AthenaES AE-0107) and cultivated at 37°C with agitation at 150 rpm. The growth curve was monitored by measuring the D.O hourly to track growth (ln(DO) over time). During the exponential growth phase of the bacteria (D.O=0.8-1), 1 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside) was added to the culture medium to induce the production of the polypeptide. The culture was then continued until reaching the stationary phase. Subsequently, bacterial pellets were harvested by centrifugation (4000g, 10 minutes at 4°C), separated from the supernatant, and frozen at -20°C.

For protein extraction, bacteria were lysed in a lysis buffer (PBS1X, 500 mM NaCl, 10 mM MgCl₂, 0.5% Triton X100 – volume equal to 1/10th of the bacterial culture volume). The lysis buffer was supplemented with protease inhibitors (cOmplete™ Protease Inhibitor Cocktail, Roche), DNase (100 µg/mL), and lysozyme (10 mg/mL). The lysate was incubated for 30 minutes on a rotator at 4°C and then subjected to sonication (2 rounds of 5 minutes, pulse 3 seconds, amplitude 30). Cellular debris and the insoluble fraction were separated from the soluble fraction by centrifugation (15000g, 15 minutes at 4°C). The soluble fraction was stored

at 4°C, while the insoluble fraction was resuspended in a urea buffer (PBS1X, 8M urea, 500 mM NaCl, volume equal to 1/4th of the lysis buffer volume). This resuspended fraction was supplemented with DNase (100 µg/mL) and incubated for 1 hour on a rotator at 4°C. Proteins released into the buffer were collected in the supernatant by centrifugation (15000g, 15 minutes at 4°C) and combined with the previously saved soluble fraction.

The entire polypeptide was subsequently purified by affinity chromatography using Ni-NTA beads (745400 Propino, Machery-Nagel, volume equal to 1/1000th of the bacterial culture volume). The beads, pre-washed with PBS1X, were added to the protein suspension and incubated for 1 hour on a rotator at 4°C. The beads were then loaded onto a column (with a cotton filter that did not exceed the bead size), and the non-retained fraction was removed by aspiration using a peristaltic pump (1 mL/minute). The beads were further washed with 1M NaCl bead volume, followed by five volumes of a washing buffer (PBS1X, 500 mM NaCl, 10 mM MgCl₂, 15 mM imidazole).

Subsequently, the polypeptide was eluted from the Ni-NTA beads by adding an elution buffer (PBS1X, EDTA 50 mM, volume approximately 10 times that of the bead volume) and quantified using the Pierce™ BCA Protein Assay Kit. Without delay, the polypeptide in solution was supplemented with 1 mM DTT (dithiothreitol) and digested by adding TEV protease (Produced by the Protein Science Facility – SFR Bioscience – 0.5 mg TEV for 10 mg of protein). The mixture was placed in a dialysis bag rinsed with PBS1X (MWCO: 3500 Da) and dialyzed against a solution of PBS1X and 500 mM NaCl overnight at 4°C. The cleaved peptide was finally purified by adding Ni-NTA beads as previously described (1 mL of beads per 50 mg of peptide) for 1 hour on a rotator at 4°C. After placing the peptide-bead suspension on an identical column as before, the cleaved peptide was recovered in the non-retained fraction, quantified, aliquoted, and frozen at -80°C.

N-TAILS sample set-up and mass spectrometry parameters

N-TAILS experiment was used to identify the free amines on the N-terminal part of the GPRC5A cleaved part by mass spectrometry. N/TERT-1 keratinocytes were transfected with an overexpression plasmid containing the C-terminal region of GPRC5A linked to a GFP tag (see the sequence in **Table S5**). Subconfluent cells were transfected using 2 µg/ml of plasmid and Lipofectamin 2000 reagent (Life Technologies) according to the manufacturer's instructions. After 24 hours, total proteins were extracted and labelled with some isobar TMTsixplex™ kit following the manufacturer's instructions (28).

Briefly, the six samples (160 µg of total protein per condition) were dissolved in 180 mM HEPES pH 8 and reduced with 10 mM Tris (2-carboxyethyl) phosphine, alkylated with 25 mM iodoacetamide. Samples were cleaned and concentrated by using SP3 beads (29) before labeled with one TMT label (126, 127N; TMT 10-plex kit 90110 from Thermo Scientific), dissolved in DMSO in a 1:5 (total protein/TMT label) mass ratio for 60 min. Labeling reactions were stopped by incubation with 5% hydroxylamine (Sigma) for 30 min. Before digestion, all samples were combined in Hepes 180mM and trypsin was added (trypsin/total protein (1:100); Trypsin V511A, Promega) overnight at 37°C. N-terminal peptide enrichment was performed on the digested sample by removing the internal tryptic peptides with undecanal (Sigma, U2202). Enriched N-terminal peptides were then desalted with a C18 spin column (Thermo Fisher Scientific) and the eluate fraction was freeze-dried, resuspended in 0.1% formic acid and analyzed by LC-MS/MS on a Q-Exactive HF mass spectrometer (three replicates), as described for ATOMS experiments. Data files were analyzed with Proteome Discover 2.4 using the SEQUEST HT algorithm against the human protein database (SwissProt release 2019-12, 43835 entries). Precursor mass tolerance and fragment mass tolerance were set at 10 ppm and 0.02 Da, respectively, and up to 2 missed cleavages were allowed. Oxidation (M, P), pyroglutamate N-term (Q, E), acetylation (Protein N-terminus), and TMT6Plex (N-term, K) were set as variable modifications, and carbamidomethylation (C) as fixed modification.

Cathepsin G digestion

In vitro digestions were performed using purified Cathepsin G to prove the ability of the protease to digest the C-terminal region of the GPRC5A receptor. 3µg of purified mimetic C-ter polypeptide produced in bacteria were submitted to 0.001 unity of Cathepsin G (C4428, Sigma Aldrich) for 1 or 2 hours, at 37°C. Then digested peptides were analysed on polyacrylamide gel, stained with Coomassie thereafter.

Statistical analysis

All data were presented as mean \pm SD for at least three independent experiments or three replicates, except when indicated. Statistical significance ($p < 0.05$) was determined by performing adapted statistical test as indicated in figure legends. All analyses were performed with GraphPad Prism 10 software.

RESULTS

Searching for new mechanosensitive candidates in human primary keratinocytes (2D).

To identify new mechanosensing receptors involved in keratinocyte mechanotransduction, we conducted a genome-wide expression analysis by RNA-sequencing of human primary keratinocytes cultured on glass surface (Glass), and on a soft substrate (Soft) by using polyacrylamide hydrogels. All cells were culture-conditioned for 3 days and cells on soft hydrogels were also replated on glass surface (Soft_glass) for 24 h (**Figure 1**). Analysis revealed a strong signature of Glass condition compared to Soft and Soft_glass conditions (**Figure 1a**). However, 44 genes were specifically overexpressed when cells were replated on Glass (**Figure 1b, Table S2**). One of the most significantly upregulated genes was the G protein-coupled receptor class C family 5 member A (GPCR5A) (**Figure 1c, Table 1**), which suggest a potential candidate for keratinocyte mechanotransduction. To confirm this, GPCR5A expression was analyzed after a 72-hour preconditioning period on different substrate rigidities (soft, medium, and rigid hydrogels or glass), prior replating on glass substrate for 24 h. GPCR5A expression was significantly overexpressed during the transition from hydrogels to glass substrate while no significant difference was observed from glass to glass replating (**Figure 1d-g**). Consequently, the greater the difference between the initial and final substrates, the stronger the expression of GPCR5A (up to a six-fold increase between the soft and the glass conditions). Collectively, these initial results indicate a mechanosensitive role for the GPCR5A receptor in human keratinocytes.

GPCR5A expression in homeostatic and altered human skin.

GPCR5A is predominantly localized peri- and intra-nuclearly in the differentiated healthy human epidermis (**Figure 2a**). However, observations 4 days after burn in an *ex vivo* human skin model have indicated that the receptor's expression is transferred from differentiated layers

to the basal migrating keratinocytes (**Figure 2b**), in a similar manner as previously observed by Aragona et al (15), suggesting a potential role in the re-epithelialization process. Additionally, a spatiotemporal expression pattern was observed. Receptor expression was completely lost during the initial day post-burn and then restored after 4 days in culture, in migrating keratinocytes (**Figure S1**). Similarly, keratin 14 was completely absent in the damaged area at D0. Subsequently, from day 4 to day 12, its expression was restored in the basal keratinocytes at the wound edges, corresponding to proliferating and migrating cells (**Figure S1, S2 and movie 1**).

At this juncture, a notable observation emerged when utilizing two distinct antibodies to label each end of the GPRC5A receptor. While only the cytoplasm of cells was labeled by an anti-N-terminal GPRC5A antibody (anti-GPRC5A-Nterm), an anti-C-terminal GPRC5A antibody (anti-GPRC5A-Cterm) exhibited two distinct signals in the cytoplasm and in the nucleus, respectively (**Figure S3**). Further experiments using cultured primary human keratinocytes under different substrate conditions yielded similar results when transferring cells from soft to stiff substrates (**Figure 3b-c**).

GPRC5A translocation.

To gain further insight into the role of GPRC5A in keratinocytes, the localization of GPRC5A was examined at various time points using two distinct antibodies (**Figure 3a**). We observed that GPRC5A undergoes dynamic changes during the adhesion and differentiation of keratinocyte. Notably, in cellular suspensions, both antibodies identified the receptor in a perinuclear compartment (**Figure 3b-c**). However, during the initial stages of cell adhesion and early differentiation, while the anti-N-terminus staining remained perinuclear, the anti-C-terminus antibody indicated a relocation of this region of the receptor into the nucleus. However, during the differentiation phase, there was a notable decrease in GPRC5A C-terminal region expression within the nucleus, which appeared to return to cytoplasmic vesicular

compartments (**Figure 3b**). Subsequent co-immunolabeling experiments demonstrated that the GPRC5A C-terminal region colocalized with specific endomembrane organelles, including the endoplasmic reticulum and the Golgi apparatus (**Figure 3d**). Immunolabeling using the anti-GPRC5A-Nterminal region antibody also showed an association with the endoplasmic reticulum and the Golgi apparatus (**Figure S4**).

This observation is of particular interest due to its concurrent timing with the upregulation of receptor expression following the transition from a soft substrate to a rigid one. Specifically, the receptor's transcriptional increase extends up to 24 h after cells adhere to their substrate, while the translocation of GPRC5A C-terminal region into the nucleus also begins within the first 30 min post-adhesion and persists until cell differentiation.

To date, the cleavage site of the C-terminal portion of GPRC5A has not been reported. GPRC5A cleavage was then analyzed in NHEK, 24 h post-seeding, using a N-terminal amine isotopic labeling (TAILS) technique. Mass spectrometry (LC-MS/MS) analyses revealed 3 cleavage sites at positions 269, 321 and 336, with a more abundant cleavage site corresponding to the YAPY↓321STHF sequence (**Table 2**). A bioinformatic analysis identified the cathepsin G as a potential proteolysis candidate. To investigate this further, we treated a recombinant peptide corresponding to the cytoplasmic C-terminal domain of GPRC5A (C-ter peptide) designed at the laboratory, with purified cathepsin G. Gel analysis following digestion revealed that the peptide could indeed be cleaved by the cathepsin G in less than 2 h under physiological conditions (**Figure S5**).

To confirm the presence of the cathepsin G protease, protein extracts from primary keratinocytes were subjected to western blot analysis (**Figure 4a**). A 25 kDa band corresponding to purified cathepsin G was observed in keratinocyte extracts. This finding was further validated by immunofluorescence, which demonstrated the presence of cathepsin G in the perinuclear region of keratinocytes (**Figure 4b**).

To investigate the role of cathepsin G in the cleavage and translocation of the C-terminal part of GPRC5A, a specific protease inhibitor (shown to be cell permeable and specific in dendritic cells (30)) was used on keratinocytes cultured on hydrogels with stiffness ranging from 4 to 14 kPa for 3 days before transfer onto glass slides to induce the nuclear translocation. Confocal microscopy confirmed nuclear translocation in non-treated cells, while the nuclear labelling was reduced after 4 h with the cathepsin G inhibitor (**Figure 4c-d**). This indicates the potential involvement of this protease in the cleavage of the C-terminal part of GPRC5A. These results collectively indicate that cathepsin G may be involved in the cleavage of the C-terminal region of GPRC5A.

GPRC5A impacts adhesion and cell survival pathways in keratinocyte.

In order to better understand the influence of GPRC5A on signaling pathways in keratinocytes, a phosphoprotein array was conducted following the adhesion of a GPRC5A knocked-down (KD) N/TERT-1 keratinocyte cell line (lentiviral infection of shRNA targeting GPRC5A sequence, sh-GPRC5A, or control sh-CTRL) 2 h and 24 h after replating on a plastic surface. The repression of GPRC5A was validated at both the RNA and protein levels (**Figure 5a-b**). This was also demonstrated in primary keratinocytes using a siRNA approach (**Figure S6**). The phosphorylation rate of 43 kinases and 2 related total proteins was analyzed (**Figure S7-S8**). The histograms in figures 5d represent the spot density of the most impacted kinases and the two total proteins (**Figure 5c-d**). This indicated a two-fold increase in phosphorylation of JNK (jun N-terminal kinase), and a four-fold increase of FAK (Focal adhesion kinase) phosphorylation (Y397) in GPRC5A^{KD}. Additionally, a slight increase in Src protein phosphorylation (Y419) was observed, while β -catenin was not affected by the absence of GPRC5A.

Furthermore, we observed a three-fold increase in PRAS40 phosphorylation (T246), and a two-fold increase in AKT (S473) and p53 (S15) phosphorylation in GPRC5A^{KD} cells. Finally,

HSP60 total protein exhibited a two-fold increase in GPRC5A^{KD} cells, which could be linked to a stressful environment for cells in the absence of the GPRC5A receptor. We observed a time-dependent effect on protein phosphorylation, with an increase from the early stages of cell adhesion at 2 h post-adhesion, compared with the 24 h condition (**Figure S8**).

To validate these findings, the experiment was replicated using new batches of cells, and Western blot analyses were conducted with a specific focus on Akt (**Figure 5e-f**). The labelling of S473 phosphorylation showed an increase in GPRC5A^{KD} cells (**Figure 5e**). These findings strongly suggest a close association between GPRC5A and signaling pathways regulating cell adhesion mechanisms.

GPRC5A functionality in human keratinocytes.

The study also examined the effects of GPRC5A knockdown on keratinocyte behavior *in vitro*, focusing on proliferation, adhesion, and migration. To gain insight into the role of the C-terminal domain in regulating these processes, a synthetic polypeptide mimicking this sequence of GPRC5A (C-ter peptide) was introduced to the knockdown cells. This peptide was effectively internalized by cells (**Figure S9**).

To ascertain whether GPRC5A knockdown could impact the keratinocyte proliferation process, we measured cell viability and DNA concentration over time. The results showed that GPRC5A inhibition had no effect on cell proliferation (**Figure 6a-b** and **Figure S10a-b**). Based on our previous staining of GPRC5A at leading edges, we proceeded to test whether GPRC5A deficiency could impair keratinocyte adhesion. We evaluated the capacity of GPRC5A^{KD} cells and control cells to adhere to ECM components, such as type I collagen. Our results indicate that GPRC5A^{KD} cells exhibited a 2-fold increase in adhesion efficiency compared to control cells. This enhanced adhesion was observed as early as 5 minutes after seeding and persisted for up to 120 minutes (**Figure 6c** and **Figure S10c**).

Cell adhesion to the ECM is closely linked with their capacity to migrate during the wound healing process. We then analyzed the performance of GPRC5A^{KD} cells in a standardized migration assay. The results demonstrated that GPRC5A inhibition resulted in a reduction in migration compared to the control (**Figure 6d-e** and **Figure S10d-e**), confirming a causal relationship between GPRC5A expression and adhesion/migration processes.

The role of the C-terminal part of GPRC5A was confirmed when GPRC5A^{KD} keratinocytes demonstrated a partial restoration of their adhesion and migration capacities after being treated with the recombinant peptide (**Figure 6f-g**). Indeed, both a decrease in keratinocytes adhesion and an increase in their migration were detected 24 hours after treatment.

These results demonstrate that GPRC5A is implicated in the regulation of keratinocyte adhesion and migration. They also show that the C-terminal region of the receptor has a compensatory effect on these mechanisms, leading to faster wound closure during scratch assays.

To investigate the role of GPRC5A in keratinocyte differentiation, we utilized a 3D-reconstructed human epidermis (RHE) model, which offers a more physiologically relevant differentiation model compared to monolayer cultures. GPRC5A expression was initially examined during the formation of reconstructed epidermis (**Figure 7a**). Immunostainings revealed that GPRC5A is expressed during the first week but decreases with longer times. This type of 3D differentiation model closely mimics both organogenesis and a form of wound healing, involving the proliferation and subsequent differentiation of keratinocytes. This transient expression pattern suggests a role for GPRC5A during the early stages of keratinocyte differentiation.

Subsequently, GPRC5A^{KD} cells were employed to generate RHE and evaluate the epidermal morphology after 16-days of air/liquid interface culture (**Figure 7b**). The results demonstrated that GPRC5A inhibition resulted in a decrease in epidermal thickness (**Figure 7c**).

Immunostainings of keratinocyte differentiation markers confirmed the impairment of the differentiation process, as evidenced by significantly reduced expression of Keratin 10 and a discontinuous involucrin expression pattern (**Figure 7b**).

Based on these observations, GPRC5A^{KD} RHE were treated with the mimetic polypeptide one day prior to exposure to the air/liquid interface. The results of the haematoxylin-eosin staining revealed an increase in epidermal thickness and an augmentation in the number of cell layers (**Figure 7b-c**). The positive effect on epidermal stratification was further confirmed by the restored expression of terminal differentiation markers, including Keratin 10, and to some extent, involucrin (**Figure 7b**). Finally, transepidermal water loss (TEWL) measurements were conducted to evaluate the inside-out permeability of the RHE barrier function (**Figure 7d**). These measurements indicated a reduction in water loss from the polypeptide-treated GPRC5A^{KD} RHE, with TEWL readings approaching those obtained for the control RHE. This suggests that such treatment has a beneficial impact on the integrity of the epidermal barrier.

These results indicate that the GPRC5A receptor, and more particularly its C-terminal region, plays a role in regulating keratinocyte adhesion, migration, in epidermal differentiation, and stratification.

DISCUSSION

This study provides evidence that GPRC5A plays a key role in keratinocyte behavior and epidermis stratification. We demonstrate that GPRC5A expression is upregulated in response to increased substrate stiffness, with a differential expression of GPRC5A directly linked to the difference between the initial and the final substrate rigidity. This suggests a potential function of the receptor in keratinocyte mechanosensing.

It is widely acknowledged that the mechanical properties of the dermis are disrupted during the wound healing process, with the formation of the granulation tissue (11). The sudden rise in ECM stiffness may also contribute to the specific location of GPRC5A observed in migrating keratinocytes at the leading edges during reepithelization. This finding is consistent with previous observations made in mouse wound healing models where GPRC5A displayed similar spatiotemporal expression from day 1 to day 10 post-lesion (15). Once the mouse epidermis has been repaired, GPRC5A is no longer expressed. However, in the human differentiated epidermis, it remains constitutively expressed.

GPRC5A is an orphan receptor, and its short N-terminal sequence prevents it from binding a ligand (31). Despite attempts to induce ligand stimulation by substituting the N-terminal sequence with that of metabotropic glutamate receptor 1, no activity could be demonstrated (32). While the function of GPRC5A in healthy tissue remains unclear, its expression level has been linked to the activation of various signaling pathways in different tumor contexts. This may contribute to its potential tumor-suppressing or oncogenic roles, depending on the context. For instance, it has been associated with a tumor-suppressing role in lung and oral mucosa tissues, an oncogenic role in gastrointestinal tissues, and both roles in breast tissues (33). These contradictory roles can be explained in several ways, depending on: i) its location at the plasma membrane, in perinuclear vesicles, or in the nucleus; ii) its level of expression in healthy tissue, which may or may not be high; and iii) the cell type under consideration, offering different

protein partners. Therefore, in the lung, where GPRC5A is highly expressed, its depletion results in overactivation of the STAT3 pathway, which promotes cell survival, cell transformation, and, consequently, tumor formation (34). In contrast, in the colon, where GPRC5A is minimally expressed in healthy tissue, a pronounced elevation in expression is observed in colorectal cancer, accompanied by an increase in vanin-1 activity and subsequent oxidative stress (35). However, there is currently no direct evidence that GPRC5A is involved in this process. Some have proposed that post-translational modifications of GPRC5A (N-glycosylation and serine phosphorylations) may be involved, while others suggest that GPRC5A mRNA may have a reciprocal impact on certain miRNA families and thus on their targets. It is also possible that overexpression or depletion of GPRC5A may have indirect consequences on cell survival, proliferation, adhesion, and migration in a tissue-specific manner (33-37). According to data from the Human Protein Atlas (proteatlas.org), GPRC5A expression in the skin is considered low. However, according to our results, and previous data in mice (15), an increase in its expression in injured epidermis appears to be linked to repair processes rather than hyperproliferation.

The immunofluorescent staining of GPRC5A reveals a dynamic relocation of the GPRC5A C-terminal region from the cytoplasm to the nucleus during keratinocyte adhesion and differentiation. The distinctive feature of having its C-terminal portion cleaved and directed to the nucleus makes GPRC5A a highly unconventional receptor. Presently, only a few transmembrane receptors have been reported to potentially localize within the nucleus, either in their entirety or as cleaved fragments (38, 39). Furthermore, in 2006, Cook et al. demonstrated that the angiotensin II type 1 receptor, which is also a GPCR, could undergo cleavage (40). They observed an accumulation of the C-terminal cytoplasmic portion of the protein within the nuclei of endothelial cells. This phenomenon was associated with altered signal transduction and cell proliferation, indicating that such cleavage serves as a regulatory

mechanism for a biological function. To date, no receptor has demonstrated similar activity in the cutaneous context, specifically within keratinocytes. The GPRC5A receptor, which is localized intracellularly and not at the plasma membrane like other GPCRs, appears to function in a manner that is currently undocumented in the literature. While the current literature does not provide insight into the mechanisms involved in the subsequent translocation of the C-terminal portion of GPRC5A to the nucleus, we have identified cathepsin G as the enzyme responsible for cleaving the GPRC5A C-terminal region. This enzyme is known to be primarily synthesized by immune cells in both secreted and intracellular forms (41, 42). It is also present in certain non-myeloid cells, including endothelial cells, smooth muscle cells, astrocytes, and fibroblasts (43, 44). Consequently, this immune protease is not restricted to the inflammatory response. It is also involved in various physiological processes, including muscle contraction, epithelial renewal and tissue remodeling (45). Cathepsin G's main function is to cleave intracellular proteins in order to activate them (46). However, it also has the ability to cleave extracellular matrix proteins, which promotes immune cell migration (47). To date, no study has reported cathepsin G activity in keratinocytes. However, single-cell analyses conducted on mouse skin have highlighted its expression in the basal keratinocytes of the interfollicular epidermis (<https://kasperlab.org/mouseskin>, accessed on 01/10/2023). Furthermore, the results obtained during this work have also demonstrated the expression of this enzyme in primary cultured keratinocytes. While further verification of cathepsin G expression in whole human epidermis would provide additional support for these findings, we can reasonably assume, based on the co-localization of the enzyme in the Golgi apparatus of keratinocytes (**Figure S11**), that an interaction with the C-terminal region of GPRC5A receptor in the Golgi apparatus lumen is probable. Finally, the inhibition of the enzyme's activity, which lead to a significant reduction in the translocation of the receptor's C-terminal domain into the nucleus, also suggests an interaction between the two proteins.

The GPRC5A signaling cascade in the skin remains to be fully elucidated. However, thanks to the analysis of different kinases phosphorylation, this study brings new evidence about the signaling pathways involved downstream of GPRC5A. Two main pathways were as being upregulated by GPRC5A knockdown during the initial stages of cell adhesion. These were the FAK/JNK and AKT/PRAS40/p53 pathways. FAK participates in the formation of focal adhesions between cells and the extracellular matrix, and it mediates an integrin-dependent signal transduction. It was found to be upregulated, phosphorylated, and redistributed to focal adhesion during keratinocytes adhesion (48) and more particularly during wound healing process (49), suggesting a functional role of FAK in cell migration. FAK also regulates numerous signaling pathways, including PI3K/Akt and MAPK - Erk1/2, JNK - which are closely related to cell proliferation and migration (50, 51). Our results indicate that the inhibition of GPRC5A results in the activation of these pathways, which in turn leads to an exacerbation of keratinocytes adhesion, causing a slowed migration. This is consistent with our observation of an increase in cell adhesion in GPRC5A^{KD} cells. More investigations are required to gain a fuller understanding of the underlying mechanism. Indeed, in different epithelial cancer cells, it was demonstrated that GPRC5A inhibition could result in a decrease of adhesion and cell spreading on Matrigel. This was attributed to a loss of FAK phosphorylation due to the inhibition of β 1-integrin signaling (36). Our findings are therefore at odds with the aforementioned results. In keratinocytes, GPRC5A^{KD} led to a significant increase in FAK phosphorylation at the same site (Y397). This discrepancy may be attributed to the experimental setting, as our cells were seeded on plastic dishes, whereas Bulanova's study employed Matrigel[®] coatings. Another potential explanation for this discrepancy may be attributed to the cell type under consideration – breast cancer epithelial cells or keratinocytes – showing that this receptor can exhibit opposing functions. Akt is the downstream effector of PI3K, which is activated by phosphorylation. It activates the TOR/PRAS40 kinase axis, which

regulates protein synthesis, as well as GSK-3, which acts on cell cycle. In more precise terms, upregulation of the Akt/mTOR signaling pathway has been shown to increase oral epithelial cell proliferation and migration, thereby accelerating the wound healing process (52). In physiological conditions, mTORC1 regulates MDM2 levels, which maintain low p53 protein expression (53). Because tissue repair involves rapid increases in cell proliferation, it is logical to anticipate a decrease in p53 levels to accommodate the sudden need for cellular growth. However, hyperactivation of Akt can result in a mTORC1-dependent increase in p53 translation, in addition to MDM2 sequestration in the nucleolus, inhibiting p53 ubiquitination, leading to a p53 accumulation and to further cellular senescence (54). Our study revealed that the lack of GPRC5A resulted in increased activation of the Akt pathway. Specifically, there was a two-fold increase in p53 phosphorylation on the S15 residue, which is involved in the cellular stress response. Another indicator of cellular stress is the increase in total protein HSP60 in sh-GPRC5A cells. In addition to its normal, non-stressful physiological function, this mitochondrial protein also acts as a chaperone when cells are exposed to stress factors. Moreover, it can play a role in regulating apoptosis by interacting directly with key components of the apoptotic pathway. The increase in this protein in GPRC5A^{KD} cells could correspond to a stressful environment. However, whether the lack of GPRC5A contributes to keratinocyte senescence remains to be determined.

In conclusion, our findings demonstrate that GPRC5A plays a novel role in keratinocyte mechanotransduction during skin wound healing. This receptor appears to be involved in regulating the adhesion and migration pathways, as well as the early stages of differentiation. These discoveries demonstrate the potential for using this protein as a target to enhance the reepithelization phase during the skin wound healing process. Specifically, by using a polypeptide that mimics the C-terminal region of the receptor, we were able to partially restore a wild-type phenotype, suggesting that this part of the receptor is essential for intracellular

signaling. However, further functional studies will now be required to identify the role of GPRC5A in the nucleus.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author (RD).

RNA-Seq data: Gene Expression Omnibus GSE248355
(<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248355>).

The mass spectrometry proteomics data have been deposited to the Center for Computational Mass Spectrometry repository (University of California, San Diego) via the MassIVE tool with the dataset identifier MassIVE MSV000093119.

CONFLICT OF INTEREST STATEMENT

SC, RD, AB and FN are co-inventors of the patent WO2023214086 related to the present study.

AUTHOR CONTRIBUTIONS

Conceptualization: RD, BF, FN

Formal Analysis: SC, CY, RD

Funding acquisition: RD, BF

Investigation: SC, CY, RD, AB, CD, GLP

Methodology: SC, CY, RD, GLP

Project Administration: RD, BF

Supervision: RD

Visualization: SC, CY, RD

Writing – Original Draft Preparation: SC, CY, RD

Writing – Review and Editing: SC, CY, GLP, CD, SVLG, BF, RD.

ACKNOWLEDGEMENTS

This work was supported by Isispharma France. Choua Ya is a recipient of a PhD grant from the French National Association of Research and Technology (ANRT). Sarah Chanteloube is supported by a PhD grant from the French ministry of Higher Education and Research.

We acknowledge the contribution of Catherine Moali, and the SFR Biosciences (UMS3444/CNRS, US8/Inserm, ENS de Lyon, UCBL) facilities: the staff of PSF (Protein Science Facility), especially Frédéric Delolme and Adeline Page, for their help in analyzing the mass spectrometry experiment; the IGFL's sequencing platform for RNA-seq library preparation and sequencing.

We acknowledge the contribution of SFR Santé Lyon-Est (UAR3453 CNRS, US7 Inserm, UCBL) facility : CIQLE (a LyMIC member), especially Denis Ressnikoff, Bruno Chapuis, Annabelle Bouchardon and Smatti Batoule for their help in confocal microscopy acquisition and histology sample preparation.

REFERENCES

1. Jaalouk, D. E., and Lammerding, J. (2009) Mechanotransduction gone awry. *Nat Rev Mol Cell Biol* **10**, 63-73
2. Wang, N., Tytell, J. D., and Ingber, D. E. (2009) Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus. *Nat Rev Mol Cell Biol* **10**, 75-82
3. Wong, V. W., Akaishi, S., Longaker, M. T., and Gurtner, G. C. (2011) Pushing back: wound mechanotransduction in repair and regeneration. *J Invest Dermatol* **131**, 2186-2196
4. Lumpkin, E. A., and Caterina, M. J. (2007) Mechanisms of sensory transduction in the skin. *Nature* **445**, 858-865
5. Mikesell, A. R., Isaeva, O., Moehring, F., Sadler, K. E., Menzel, A. D., and Stucky, C. L. (2022) Keratinocyte PIEZO1 modulates cutaneous mechanosensation. *Elife* **11**
6. Wang, Y., Wang, G., Luo, X., Qiu, J., and Tang, C. (2012) Substrate stiffness regulates the proliferation, migration, and differentiation of epidermal cells. *Burns* **38**, 414-420
7. You, H., Padmashali, R. M., Ranganathan, A., Lei, P., Girnius, N., Davis, R. J., and Andreadis, S. T. (2013) JNK regulates compliance-induced adherens junctions formation in epithelial cells and tissues. *J Cell Sci* **126**, 2718-2729
8. Chen, S., Shi, J., Xu, X., Ding, J., Zhong, W., Zhang, L., Xing, M., and Zhang, L. (2016) Study of stiffness effects of poly(amidoamine)-poly(n-isopropyl acrylamide) hydrogel on wound healing. *Colloids Surf B Biointerfaces* **140**, 574-582
9. Kenny, F. N., and Connelly, J. T. (2015) Integrin-mediated adhesion and mechanosensing in cutaneous wound healing. *Cell Tissue Res* **360**, 571-582
10. Diller, R. B., and Tabor, A. J. (2022) The Role of the Extracellular Matrix (ECM) in Wound Healing: A Review. *Biomimetics (Basel)* **7**

11. Hinz, B. (2010) The myofibroblast: paradigm for a mechanically active cell. *J Biomech* **43**, 146-155
12. Erdogmus, S., Storch, U., Danner, L., Becker, J., Winter, M., Ziegler, N., Wirth, A., Offermanns, S., Hoffmann, C., Gudermann, T., and Mederos, Y. S. M. (2019) Helix 8 is the essential structural motif of mechanosensitive GPCRs. *Nat Commun* **10**, 5784
13. Lin, H. H., Ng, K. F., Chen, T. C., and Tseng, W. Y. (2022) Ligands and Beyond: Mechanosensitive Adhesion GPCRs. *Pharmaceuticals (Basel)* **15**
14. Xu, J., Mathur, J., Vessieres, E., Hammack, S., Nonomura, K., Favre, J., Grimaud, L., Petrus, M., Francisco, A., Li, J., Lee, V., Xiang, F. L., Mainquist, J. K., Cahalan, S. M., Orth, A. P., Walker, J. R., Ma, S., Lukacs, V., Bordone, L., Bandell, M., Laffitte, B., Xu, Y., Chien, S., Henrion, D., and Patapoutian, A. (2018) GPR68 Senses Flow and Is Essential for Vascular Physiology. *Cell* **173**, 762-775 e716
15. Aragona, M., Dekoninck, S., Rulands, S., Lenglez, S., Mascre, G., Simons, B. D., and Blanpain, C. (2017) Defining stem cell dynamics and migration during wound healing in mouse skin epidermis. *Nat Commun* **8**, 14684
16. Liu, M., Saeki, K., Matsunobu, T., Okuno, T., Koga, T., Sugimoto, Y., Yokoyama, C., Nakamizo, S., Kabashima, K., Narumiya, S., Shimizu, T., and Yokomizo, T. (2014) 12-Hydroxyheptadecatrienoic acid promotes epidermal wound healing by accelerating keratinocyte migration via the BLT2 receptor. *J Exp Med* **211**, 1063-1078
17. Pilar Pedro, M., Lund, K., Kang, S. W. S., Chen, T., Stuelten, C. H., Porat-Shliom, N., and Iglesias-Bartolome, R. (2023) A GPCR screening in human keratinocytes identifies that the metabolite receptor HCAR3 controls epithelial proliferation, migration, and cellular respiration. *bioRxiv*
18. Ya, C., Carranca, M., Sigauco-Roussel, D., Faure, P., Fromy, B., and Debret, R. (2019) Substrate softness promotes terminal differentiation of human keratinocytes without

- altering their ability to proliferate back into a rigid environment. *Arch Dermatol Res* **311**, 741-751
19. Dickson, M. A., Hahn, W. C., Ino, Y., Ronfard, V., Wu, J. Y., Weinberg, R. A., Louis, D. N., Li, F. P., and Rheinwald, J. G. (2000) Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. *Mol Cell Biol* **20**, 1436-1447
 20. Tse, J. R., and Engler, A. J. (2010) Preparation of hydrogel substrates with tunable mechanical properties. *Curr Protoc Cell Biol* **Chapter 10**, Unit 10 16
 21. Liao, Y., Smyth, G. K., and Shi, W. (2013) The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. *Nucleic Acids Res* **41**, e108
 22. McCarthy, D. J., Chen, Y., and Smyth, G. K. (2012) Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res* **40**, 4288-4297
 23. Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., and Smyth, G. K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**, e47
 24. Robinson, M. D., McCarthy, D. J., and Smyth, G. K. (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139-140
 25. Law, C. W., Chen, Y., Shi, W., and Smyth, G. K. (2014) voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. *Genome Biol* **15**, R29
 26. Goodwin, A. E., and Pauli, B. U. (1995) A new adhesion assay using buoyancy to remove non-adherent cells. *J Immunol Methods* **187**, 213-219

27. Le Provost, G. S., Debret, R., Cenizo, V., Aimond, G., Pez, F., Kaniewski, B., Andre, V., and Sommer, P. (2010) Lysyl oxidase silencing impairs keratinocyte differentiation in a reconstructed-epidermis model. *Exp Dermatol* **19**, 1080-1087
28. Weng, S. S. H., Demir, F., Ergin, E. K., Dirnberger, S., Uzozie, A., Tuscher, D., Nierves, L., Tsui, J., Huesgen, P. F., and Lange, P. F. (2019) Sensitive Determination of Proteolytic Proteoforms in Limited Microscale Proteome Samples. *Mol Cell Proteomics* **18**, 2335-2347
29. Hughes, C. S., Moggridge, S., Muller, T., Sorensen, P. H., Morin, G. B., and Krijgsveld, J. (2019) Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. *Nat Protoc* **14**, 68-85
30. Reich, M., Lesner, A., Legowska, A., Sienczyk, M., Oleksyszyn, J., Boehm, B. O., and Burster, T. (2009) Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells. *Mol Immunol* **46**, 2994-2999
31. Fredriksson, R., Lagerstrom, M. C., Lundin, L. G., and Schioth, H. B. (2003) The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol Pharmacol* **63**, 1256-1272
32. Brauner-Osborne, H., Jensen, A. A., Sheppard, P. O., Brodin, B., Krogsgaard-Larsen, P., and O'Hara, P. (2001) Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D. *Biochim Biophys Acta* **1518**, 237-248
33. Zhou, H., and Rigoutsos, I. (2014) The emerging roles of GPRC5A in diseases. *Oncoscience* **1**, 765-776
34. Chen, Y., Deng, J., Fujimoto, J., Kadara, H., Men, T., Lotan, D., and Lotan, R. (2010) Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. *Cancer Res* **70**, 8917-8926

35. Zhang, L., Li, L., Gao, G., Wei, G., Zheng, Y., Wang, C., Gao, N., Zhao, Y., Deng, J., Chen, H., Sun, J., Li, D., Zhang, X., and Liu, M. (2017) Elevation of GPRC5A expression in colorectal cancer promotes tumor progression through VNN-1 induced oxidative stress. *Int J Cancer* **140**, 2734-2747
36. Bulanova, D. R., Akimov, Y. A., Rokka, A., Laajala, T. D., Aittokallio, T., Kouvonen, P., Pellinen, T., and Kuznetsov, S. G. (2017) Orphan G protein-coupled receptor GPRC5A modulates integrin beta1-mediated epithelial cell adhesion. *Cell Adh Migr* **11**, 434-446
37. Ye, X., Tao, Q., Wang, Y., Cheng, Y., and Lotan, R. (2009) Mechanisms underlying the induction of the putative human tumor suppressor GPRC5A by retinoic acid. *Cancer Biol Ther* **8**, 951-962
38. Ahmad, R., Lahuna, O., Sidibe, A., Daulat, A., Zhang, Q., Luka, M., Guillaume, J. L., Gallet, S., Guillonneau, F., Hamroune, J., Polo, S., Prevot, V., Delagrangé, P., Dam, J., and Jockers, R. (2020) GPR50-Ctail cleavage and nuclear translocation: a new signal transduction mode for G protein-coupled receptors. *Cell Mol Life Sci* **77**, 5189-5205
39. Sprinzak, D., and Blacklow, S. C. (2021) Biophysics of Notch Signaling. *Annu Rev Biophys* **50**, 157-189
40. Cook, J. L., Mills, S. J., Naquin, R., Alam, J., and Re, R. N. (2006) Nuclear accumulation of the AT1 receptor in a rat vascular smooth muscle cell line: effects upon signal transduction and cellular proliferation. *J Mol Cell Cardiol* **40**, 696-707
41. Schechter, N. M., Wang, Z. M., Blacher, R. W., Lessin, S. R., Lazarus, G. S., and Rubin, H. (1994) Determination of the primary structures of human skin chymase and cathepsin G from cutaneous mast cells of urticaria pigmentosa lesions. *J Immunol* **152**, 4062-4069
42. Stoeckle, C., Sommandas, V., Adamopoulou, E., Belisle, K., Schiekofer, S., Melms, A., Weber, E., Driessen, C., Boehm, B. O., Tolosa, E., and Burster, T. (2009) Cathepsin G

- is differentially expressed in primary human antigen-presenting cells. *Cell Immunol* **255**, 41-45
43. Abraham, C. R., Kanemaru, K., and Mucke, L. (1993) Expression of cathepsin G-like and alpha 1-antichymotrypsin-like proteins in reactive astrocytes. *Brain Res* **621**, 222-232
 44. Cavarra, E., Fimiani, M., Lungarella, G., Andreassi, L., de Santi, M., Mazzatenta, C., and Ciccoli, L. (2002) UVA light stimulates the production of cathepsin G and elastase-like enzymes by dermal fibroblasts: a possible contribution to the remodeling of elastotic areas in sun-damaged skin. *Biol Chem* **383**, 199-206
 45. Garg, M., Angus, P. W., Burrell, L. M., Herath, C., Gibson, P. R., and Lubel, J. S. (2012) Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract. *Aliment Pharmacol Ther* **35**, 414-428
 46. Dzau, V. J., Gonzalez, D., Kaempfer, C., Dubin, D., and Wintroub, B. U. (1987) Human neutrophils release serine proteases capable of activating prorenin. *Circ Res* **60**, 595-601
 47. Son, E. D., Kim, H., Choi, H., Lee, S. H., Lee, J. Y., Kim, S., Closs, B., Lee, S., Chung, J. H., and Hwang, J. S. (2009) Cathepsin G increases MMP expression in normal human fibroblasts through fibronectin fragmentation, and induces the conversion of proMMP-1 to active MMP-1. *J Dermatol Sci* **53**, 150-152
 48. Kim, L. T., Wu, J., Bier-Laning, C., Dollar, B. T., and Turnage, R. H. (2000) Focal adhesion kinase up-regulation and signaling in activated keratinocytes. *J Surg Res* **91**, 65-69
 49. Wang, Y., Zheng, J., Han, Y., Zhang, Y., Su, L., Hu, D., and Fu, X. (2018) JAM-A knockdown accelerates the proliferation and migration of human keratinocytes, and improves wound healing in rats via FAK/Erk signaling. *Cell Death Dis* **9**, 848

50. Mitra, S. K., and Schlaepfer, D. D. (2006) Integrin-regulated FAK-Src signaling in normal and cancer cells. *Curr Opin Cell Biol* **18**, 516-523
51. Oktay, M., Wary, K. K., Dans, M., Birge, R. B., and Giancotti, F. G. (1999) Integrin-mediated activation of focal adhesion kinase is required for signaling to Jun NH2-terminal kinase and progression through the G1 phase of the cell cycle. *J Cell Biol* **145**, 1461-1469
52. Castilho, R. M., Squarize, C. H., and Gutkind, J. S. (2013) Exploiting PI3K/mTOR signaling to accelerate epithelial wound healing. *Oral Dis* **19**, 551-558
53. Havel, J. J., Li, Z., Cheng, D., Peng, J., and Fu, H. (2015) Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway. *Oncogene* **34**, 1487-1498
54. Astle, M. V., Hannan, K. M., Ng, P. Y., Lee, R. S., George, A. J., Hsu, A. K., Haupt, Y., Hannan, R. D., and Pearson, R. B. (2012) AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. *Oncogene* **31**, 1949-1962

FIGURE LEGENDS

Figure 1: Transcriptomic analysis: GPRC5A expression is associated to stiffness changes.

(a) Heatmap of differentially expressed genes (FDR < 0.05) by comparing Glass (blue), soft (green) and soft_glass (red) conditions. (b) Overlap between differentially expressed genes (using gene symbol) from the analysis shown in (a), displayed as Venn diagram. (c) qRT-PCR validation of one of the topmost significant gene showed in (b): GPRC5A. One-way ANOVA, n=3 ; *** p < 0.001. (d-g) mRNA expression of GPRC5A on soft (d), medium (e), rigid stiffness (f), and glass surface (g) for 3 days and after re-plating on glass substrate. *t*-Test; * p < 0.05. Results are presents as means ± SD and were performed in at least three independents biological replicates.

Figure 2: Effect of healing on cutaneous GPRC5A expression.

GPRC5A immunostaining (red) in human healthy abdominal skin (a) or after 4 days post-burn (150°C, 3 seconds) in *ex vivo* abdominal skin (b). Nucleus were counterstained with DAPI (blue). The white arrow stands for the edge of the burn wound. Scale bars: 50 µm.

Figure 3: GPRC5A dynamic relocation during primary keratinocyte adhesion.

(a) Graphic showing the antibodies recognition sites. (b-c) GPRC5A immunostaining (red) with anti-GPRC5A C-terminus (b) and anti- GPRC5A N-terminus (c) antibodies, and nucleus (blue). Scale bars: 10µm. (d) GPRC5A immunostaining (anti-GPRC5A, red), nucleus (blue) and the nucleolus (nucleolin), the endoplasmic reticulum (Con A), the Golgi apparatus (p58k) or the endosomal vesicles (CD63) in green. Scale bars: 5µm.

Figure 4: Analysis of the C-terminal cleavage of GPRC5A.

(a) Western-blot analysis of Cathepsin-G expression in primary keratinocytes (NHEK). Purified Cathepsin G (CatG+) is used as a positive control. (b) Cathepsin-G immunostaining (green) and

nucleus (blue) in primary keratinocytes. Scale bar 20 μm . (c) GPRC5A immunostaining (red), nucleus (blue) and bright field in primary keratinocytes +/- Cathepsin-G inhibitor treatment. Scale bars 10: μm . (d) Quantification of GPRC5A nuclear fluorescence from keratinocytes treated or not with Cathepsin-G inhibitor (n=16). *t*-test; **** $p < 0.0001$.

Figure 5: Protein phosphorylation level in N/TERT1 sh-GPRC5A (GPRC5A^{KD}) vs sh-CTRL cells 24 hours post-adhesion.

(a) Validation of GPRC5A inhibition performed through qPCR and Western-blot analysis. Tests were conducted on the stable immortalized human N/TERT-1 cell line using the GPRC5A-targeting shRNA (shGPRC5A) and a control shRNA (shCTRL). One-way ANOVA test; *t*-test; ** $p < 0.01$. (b) Phosphorylation arrays 24 hours after adhesion. Each array was incubated with 200 μg of cell lysate. Dark spots on array corners represent reference spots. (c) Chart showing the analysis of the most modulated kinase and two total proteins. (d) Western-blot analysis of Akt and phospho-Akt (S473, 60kDa) expression, in N/TERT1 sh-GPRC5A and sh-CTRL cells, 24 hours post-adhesion. (e) Quantification of the relative Akt phosphorylation over time, in sh-CTRL and sh-GPRC5A cells (n=3). Multiple paired *t*-test with False Discovery Rate at 1 %; * $q < 0.05$. All results are presents as means \pm SD.

Figure 6: Knockdown of GPRC5A (GPRC5A^{KD}) results in increased cell adhesion, but a reduced cell migration.

(a-b) Proliferation assays in N/TERT-1 sh-GPRC5A and sh-CTRL cells: Alamar Blue (n=5) (a) and DNA quantification (n=4) (b). One-way ANOVA test, ns: non-significant. (c) Quantification of adhesion assay (n=3) and (e) migration assay (n=3) in N/TERT-1 sh-GPRC5A and sh-CTRL cells. (d) Yellow line represents uncovered area during migration assay. Two-way ANOVA test; * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$. (f-g) Mimetic C-ter peptide treatment effect (10 $\mu\text{g}/\text{ml}$, for 24 hours) on sh-GPRC5A cells. (f) Adhesion measured by

impedance disturbing (n=4). Two-way ANOVA test; **** $p < 0.0001$. (g) Quantification of migration assay (n=2). Two-tailed unpaired *t*-test; * $p < 0.05$. All results are presents as means \pm SD.

Figure 7: knock-out GPRC5A alters keratinocyte differentiation process.

(a) GPRC5A immunostaining (red) in 3D-reconstructed human epidermis (RHE) at 1 to 18 days post-emersion. Nucleus was counterstained with DAPI (blue). Scale bars, 100 μ m. (b) Haematoxylin-eosin staining (H&E) and immunofluorescence staining of involucrin (red), Keratin 10 (K10, red) and Keratin 14 (K14, green) in control and GPRC5A^{KD} RHE +/- treatment with GPRC5A C-ter peptide. Nuclei were counterstained with DAPI (blue). Scale bars, 50 μ m. (c) Mean epidermis thickness (in μ m), n=3. (d) RHE inside-out permeability using TEWL measurements (a.u: arbitrary unit), n=3. Kruskal-Wallis test, * $p < 0.05$, ns= non-significant.




Figure 1: Transcriptomic analysis: GPRC5A expression is associated to stiffness changes.

(a) Heatmap of differentially expressed genes (FDR < 0.05) by comparing Glass (blue), soft (green) and soft_glass (red) conditions. (b) Overlap between differentially expressed genes (using gene symbol) from the analysis shown in (a), displayed as Venn diagram. (c) qRT-PCR validation of one of the topmost significant gene showed in (b): GPRC5A. One-way ANOVA, $n=3$; *** $p < 0.001$. (d-g) mRNA expression of GPRC5A on soft (d), medium (e), rigid stiffness (f), and glass surface (g) for 3 days and after re-plating on glass substrate. t -Test; * $p < 0.05$. Results are presents as means \pm SD and were performed in at least three independents biological replicates.




Figure 2: Effect of healing on cutaneous GPRC5A expression.

GPRC5A immunostaining (red) in human healthy abdominal skin (a) or after 4 days post-burn (150°C, 3 seconds) in *ex vivo* abdominal skin (b). Nucleus were counterstained with DAPI (blue). The white arrow stands for the edge of the burn wound. Scale bars: 50 μm .




Figure 3: GPRC5A dynamic relocation during primary keratinocyte adhesion.

(a) Graphic showing the antibodies recognition sites. (b-c) GPRC5A immunostaining (red) with anti-GPRC5A C-terminus (b) and anti-GPRC5A N-terminus (c) antibodies, and nucleus (blue). Scale bars: 10 μ m. (d) GPRC5A immunostaining (anti-GPRC5A, red), nucleus (blue) and the nucleolus (nucleolin), the endoplasmic reticulum (Con A), the Golgi apparatus (p58k) or the endosomal vesicles (CD63) in green. Scale bars: 5 μ m.




Figure 4: Analysis of the C-terminal cleavage of GPRC5A.

(a) Western-blot analysis of Cathepsin-G expression in primary keratinocytes (NHEK). Purified Cathepsin G (CatG+) is used as a positive control. (b) Cathepsin-G immunostaining (green) and nucleus (blue) in primary keratinocytes. Scale bar 20 μm . (c) GPRC5A immunostaining (red), nucleus (blue) and bright field in primary keratinocytes +/- Cathepsin-G inhibitor treatment. Scale bars 10: μm . (d) Quantification of GPRC5A nuclear fluorescence from keratinocytes treated or not with Cathepsin-G inhibitor (n=16). *t*-test; **** $p < 0.0001$.




Figure 5: Protein phosphorylation level in N/TERT1 sh-GPRC5A (GPRC5A^{KD}) vs sh-CTRL cells 24 hours post-adhesion.

(a) Validation of GPRC5A inhibition performed through qPCR and Western-blot analysis. Tests were conducted on the stable immortalized human N/TERT-1 cell line using the GPRC5A-targeting shRNA (shGPRC5A) and a control shRNA (shCTR). One-way ANOVA test; *t*-test; ** $p < 0.01$. (b) Phosphorylation arrays 24 hours after adhesion. Each array was incubated with 200 μ g of cell lysate. Dark spots on array corners represent reference spots. (c) Chart showing the analysis of the most modulated kinase and two total proteins. (d) Western-blot analysis of Akt and phospho-Akt (S473, 60kDa) expression, in N/TERT1 sh-GPRC5A and sh-CTRL cells, 24 hours post-adhesion. (e) Quantification of the relative Akt phosphorylation over time, in sh-CTRL and sh-GPRC5A cells ($n=3$). Multiple paired *t*-test with False Discovery Rate at 1 %; * $q < 0.05$. All results are presents as means \pm SD.




Figure 6: Knockdown of GPRC5A (GPRC5A^{KD}) results in increased cell adhesion, but a reduced cell migration.

(a-b) Proliferation assays in N/TERT-1 sh-GPRC5A and sh-CTRL cells: Alamar Blue (n=5) (a) and DNA quantification (n=4) (b). One-way ANOVA test, ns: non-significant. (c) Quantification of adhesion assay (n=3) and (e) migration assay (n=3) in N/TERT-1 sh-GPRC5A and sh-CTRL cells. (d) Yellow line represents uncovered area during migration assay. Two-way ANOVA test; * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$. (f-g) Mimetic C-ter peptide treatment effect (10 $\mu\text{g/ml}$, for 24 hours) on sh-GPRC5A cells. (f) Adhesion measured by impedance disturbing (n=4). Two-way ANOVA test; **** $p < 0.0001$. (g) Quantification of migration assay (n=2). Two-tailed unpaired t -test; * $p < 0.05$. All results are presents as means \pm SD.







Figure 7: knock-out GPRC5A alters keratinocyte differentiation process.

(a) GPRC5A immunostaining (red) in 3D-reconstructed human epidermis (RHE) at 1 to 18 days post-emersion. Nucleus was counterstained with DAPI (blue). Scale bars, 100 μm. (b) Haematoxylin-eosin staining (H&E) and immunofluorescence staining of involucrin (red), Keratin 10 (K10, red) and Keratin 14 (K14, green) in control and GPRC5A^{KD} RHE +/- treatment with GPRC5A C-ter peptide. Nuclei were counterstained with DAPI (blue). Scale bars, 50 μm. (c) Mean epidermis thickness (in μm), n=3. (d) RHE inside-out permeability using TEWL measurements (a.u: arbitrary unit), n=3. Kruskal-Wallis test, * p < 0.05, ns= non-significant.




Figure S1: GPRC5A expression in ex vivo wound healing of human skin. GPRC5A (red) and Keratin 14 (green) immunostaining after 0-, 4-, 7- and 12-days post-burn (150°C, 3 seconds) in ex vivo abdominal skin. Nucleus were counterstained with DAPI (blue). The white arrow stands for the edge of the wound. Scale bars 25 μm.






Figure S2: Confocal imaging of GPRC5A (red) and K14 (green) co-immunostainings in ex vivo wound healing at day 4 post burn.




Figure S3: GPRC5A immunostaining (red) with anti-GPRC5A C-terminus or GPRC5A N-terminus antibodies, and nucleus (blue) in human abdominal skin. Scale bars: 20 μ m.




Figure S4: GPRC5A N-terminus immunostaining in red, nucleus counterstaining in blue, the endoplasmic reticulum (Con A), the Golgi apparatus (p58k) or the early endosome vesicles (EEA1) in green. Scale bars: 5 μ m.




Figure S5: Coomassie gel staining of the C-terminal region of GPRC5A mimetic purified polypeptide, either digested or not with Cathepsin G for 1 or 2 hours.



a**b**

Figure S6: Validation of GPRC5A inhibition by siRNA in human primary keratinocytes by qRT-PCR (a) and western blot (b). One-way ANOVA test; * $p < 0.05$ and ** $p < 0.01$.





Figure S7: Human phospho-kinase array results and coordinates (by R&D Systems). See legend of the spot position in **Table S3**.




Figure S8: Normalized data analysis of kinases phosphorylation in NTERT/1 sh-GPRC5A vs sh-CTRL cells at 2 and 24hours post-adhesion (n=2).




Figure S9: Fluorescent immunostaining of NHEK1 cells treated or not with 10 µg/ml of peptide for 12h and observed by confocal microscopy. GPRC5A (red), cellular compartment (green): early endosomes (EEA1), lysosomes (LAMP1), Golgi apparatus (p58K), endoplasmic reticulum (conA), and the nuclei (blue). Scale bars : 25 µm.




Figure S10: Knockdown of GPRC5A in NHEK cells with siRNA. (a) Proliferation assays with alamar blue test. (b) Proliferation based on DNA quantitation. (c) Quantification of adhesion assay. (d-e) Quantification of migration assay. Yellow line represents uncovered area. (a and b) One-way ANOVA test, (c and e) Two-way ANOVA test; * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$. All results are presented as means \pm SD and were performed in at least three independent biological replicates.




Figure S11: Fluorescent immunostaining of Cathepsin G (red), nuclei (blue) and cellular compartments (green) : early endosome (EEA1), Golgi apparatus (p58K), Lysosome (LAMP1) and the endoplasmic reticulum (ConA). Scale bare 10 μ m. The zoom in (+) zone shows the colocalization between the Cathepsin G in the Golgi apparatus.